Investment strategy

Base case for transitory inflation remains intact

16 August 2021 • 8 mins read

Our base case has been that the surge in inflationary pressures over the summer months to levels significantly above the US Federal Reserve’s long term 2% target is unlikely to be sustained into 2022, although the post-pandemic environment ahead with faster growth means inflation could remain elevated at or moderately above central banks’ target.

This scenario is so far consistent with the US inflation data for the month of July, which showed that many of the factors contributing to elevated inflation since 2Q21 have started to wane.

Headline and core CPI rose by 0.5% and 0.3% month-on-month (MoM) in July versus 0.9% for both measures in the month of June, i.e. the pace of price increases appeared to be levelling off. The biggest contributors to inflation over the past few months such as used autos has stopped rising significantly (0.2% MoM versus 10.5% in June).

Reopening categories like airfares had surprisingly eased off in July as well and shelter prices were also softer than expected. The market reaction to this positive news on inflation was relatively mixed.

The bolstering of the case for transitory inflation helped to keep equity markets relatively calm. The S&P500 closed ~0.1% higher on Wednesday and grinded higher to close the week at ~0.6% above Wednesday’s open.

A calmer inflation outlook also means lower odds of a more hawkish than anticipated path of monetary normalization from global central banks. As a result, after the release of the July US inflation data, the nominal US 10-year Treasury yield fell 2bps to 1.337% on Wednesday, and experienced a sharp move down on Friday to end the week at 1.286%.

The USD dollar index (DXY) was flat on Wednesday but mirrored the 10-year Treasury yield’s decline on Friday to end the week at 92.52 (-0.6% since Wednesday). As the long end of the US Treasury yield curve and the US dollar eased downwards, gold moved steadily higher to reach USD1778.2 (+2.8% since Wednesday) on Friday.

With the latest inflation and labor market data consistent with their base case expectations, the Fed stayed on script as Fed officials continued the pattern over the last month of priming the market for a taper announcement in 4Q 2021. Shortly after the inflation print release, Dallas Federal Reserve President Robert Kaplan said that the Fed should begin to taper its purchases of Treasury bonds and mortgage-backed securities in October.

This is one of the most aggressive calls to-date in a week of heavy Fed speak where we heard several regional presidents calling for bringing forward the tapering timeline.

Kaplan said in a television interview that if the economy unfolds in accordance to his expectations, he would be “in favor of announcing a plan at the September meeting and beginning tapering in October”. His reason was that “these purchases are very well equipped to stimulate demand, but we don’t have a demand problem in the economy”.

Although the taper announcement could come as early as the Fed’s next meeting in September, we are currently leaning towards November and December, and a lot will depend on the strength of the labor market and inflation data for August. Regardless, we believe that the Fed’s exit from quantitative easing would be gradual (between eight to 12 months), which remains over the long term broadly supportive of risk assets, albeit with the scope for sharp short-term volatility.

Our broadly constructive outlook for markets is buttressed by the progress on the massive US fiscal package by policymakers.

On Monday (9 August 2021), Senate Democrats released the long-awaited outline for their antipoverty and climate action plan with proposed spending of USD3.5 trillion for next year’s (i.e. financial year 2022) budget resolution.

This resolution sets out the blueprint for the various Congressional committees to draw up their detailed spending plans and kickstart the process for the final budget reconciliation due to take place at the end of the year, in which the Democrats are expected to utilise their narrow margin in the Senate to push through their spending priorities.

The Senate next passed the bipartisan Infrastructure Investment and Jobs Act (IIJA) by a 69-30 margin on Tuesday (10 August 2021), securing the first step of a major win for President Biden’s economic agenda to ‘Build Back Better’.

The bill comprised USD1.2 trillion worth of infrastructure spending, of which USD550 billion was new, above-baseline funding. The new spending focused on roads and bridges (USD110 billion), power infrastructure (USD65 billion), rail (USD66 billion), broadband (USD65 billion), and water projects (USD63 billion).

On Wednesday (11 August 2021), the USD3.5 trillion budget resolution passed the Senate with a 50-49 margin along party lines, i.e. no Republicans voted in favour and Democrats used their narrow majority to advance the resolution to the next stage.

Both developments are expected to increase the US government’s deficit. The Congressional Budget Office – the federal body that is charged with providing independent assessment of the economic and budgetary impact of the spending plan to Congress – estimated that the bipartisan infrastructure plan is expected to increase the federal budget deficit by USD256 billion over a period of 10 years, even though the lawmakers who put up the bill have stated that the revenues for the plan would come from sources such as the auction of the broadband spectrum.

Under the USD3.5 trillion budget resolution, spending categories amounting to USD1.75 trillion are allowed to be deficit-financed. As a result, the Senate Finance Committee which is responsible for drafting the tax increases to pay for the spending plan has been instructed to come up with a proposal to raise USD1.8 trillion in revenue over 10 years. This is expected to meet with strong opposition, even amongst some Democrats. Moderates such as Senator Joe Manchin (Dem) have already voiced their concerns with the price tag of the ambitious spending plan. The infrastructure bill now moves to Congress, where it is likely that no clear path forward or a timing to vote on the bill will emerge for the next few weeks. In the meantime, the various House and Senate committees will have until 15

September to submit their draft legislative text for the budget resolution. The spectre of Delta-variant risks continues to lurk in the backdrop for investors as daily new Covid cases continue to rise in the US. The 7-day average daily new case count in US has risen from the recent low of 11,299 in late June to 122,788 (as of 12 August), though it remains 51% below the peak of 251,085 reached in early January.

The spectre of Delta-variant risks continues to lurk in the backdrop for investors as daily new Covid cases continue to rise in the US. The 7-day average daily new case count in US has risen from the recent low of 11,299 in late June to 122,788 (as of 12 August), though it remains 51% below the peak of 251,085 reached in early January.

Two bright spots are that, in addition to data so far showing that vaccines are effective in lowering the fatalities and hospitalization rates, the rates of new cases in the UK and Europe also appear to have peaked.

In Europe ex-UK, the 7-day average rose from 11,183 in late June to a recent high of 69,972 in late July and is currently 66,185, which is 61% below the peak of 170,881 reached last November.

As for the closely watched example of the UK, the 7-day average fell from a recent high of 47,696 (21 July) to a low of 26,104 on 3 August. This has ticked up slightly to 28,050.

It remains reassuring that the 7-day average daily death counts in US, UK and Europe remain 85%, 93% and 92% respectively below their peak reached in January. Although the Delta variant has now been reported in ~40 cities in China, the number of infections remain relatively low – the recent 7-day daily case count stands at 112 cases.

In our view, we remain overall overweight in equities through an overweight position in US equities.

In fixed income, we remain overweight in Emerging Market High Yield bonds, where valuations still look relatively attractive and should offer a buffer against the adverse impact of rising rates compared to other fixed income segments.

We stay underweight in both Developed Market and Emerging Market Investment Grade bonds, where historically rich valuations leave little buffer against rising rates.

Disclaimers and Disclosures

This material is prepared by Bank of Singapore Limited (Co Reg. No.: 197700866R) (the “Bank”) and is distributed in Singapore by the Bank.

This material does not provide individually tailored investment advice. This material has been prepared for and is intended for general circulation. The contents of this material does not take into account the specific investment objectives, investment experience, financial situation, or particular needs of any particular person. You should independently evaluate the contents of this material, and consider the suitability of any product discussed in this material, taking into account your own specific investment objectives, investment experience, financial situation and particular needs. If in doubt about the contents of this material or the suitability of any product discussed in this material, you should obtain independent financial advice from your own financial or other professional advisers, taking into account your specific investment objectives, investment experience, financial situation and particular needs, before making a commitment to purchase any product.

This material is not and should not be construed, by itself, as an offer or a solicitation to deal in any product or to enter into any legal relations. You should contact your own licensed representative directly if you are interested in buying or selling any product discussed in this material.

This material  is not intended for distribution, publication or use by any person in any jurisdiction outside Singapore, Hong Kong or such other jurisdiction as the Bank may determine in its absolute discretion, where such distribution, publication or use would be contrary to applicable law or would subject the Bank or its related corporations, connected persons, associated persons or affiliates (collectively “Affiliates”) to any licensing, registration or other requirements in such jurisdiction.

The Bank and its Affiliates may have issued other reports, analyses, or other documents expressing views different from the contents of this material, and may provide other advice or make investment decisions that are contrary to the views expressed in this material, and all views expressed in all reports, analyses and documents are subject to change without notice. The Bank and its Affiliates reserve the right to act upon or use the contents of this material at any time, including before its publication.

The author of this material may have discussed the information or views contained in this material with others within or outside the Bank, and the author or such other Bank employees may have already acted on the basis of such information or views (including communicating such information or views to other customers of the Bank).

The Bank, its employees (including those with whom the author may have consulted in the preparation of this material))and discretionary accounts managed by the Bank may have long or short positions (including positions that may be different from or opposing to the views in this material or may be otherwise interested in any of the product(s) (including derivatives thereof) discussed in material, may have acquired such positions at prices and market conditions that are no longer available, may from time to time deal in such product(s) and may have interests different from or adverse to your interests.

Analyst Declaration

The analyst(s) who prepared this material certifies that the opinions contained herein accurately and exclusively reflect his or her views about the securities of the company(ies) and that he or she has taken reasonable care to maintain independence and objectivity in respect of the opinions herein.

                                                                                                   

The analyst(s) who prepared this material and his/her associates do not have financial interests in the company(ies). Financial interests refer to investments in securities, warrants and/or other derivatives. The analyst(s) receives compensation based on the overall revenues of Bank of Singapore Limited, and no part of his or her compensation was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this material. The reporting line of the analyst(s) is separate from and independent of the business solicitation or marketing departments of Bank of Singapore Limited.

The analyst(s) and his/her associates confirm that they do not serve as directors or officers of the company(ies) and the company(ies)or other third parties have not provided or agreed to provide any compensation or other benefits to the analyst(s) in connection with this material.

An “associate” is defined as (i) the spouse, parent or step-parent, or any minor child (natural or adopted) or minor step-child, or any sibling or step-sibling of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, parent or step-parent, minor child (natural or adopted) or minor step-child, or sibling or step-sibling is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

Conflict of Interest Declaration

The Bank is a licensed bank regulated by the Monetary Authority of Singapore in Singapore. Bank of Singapore Limited, Hong Kong Branch (incorporated in Singapore with limited liability), is an Authorized Institution as defined in the Banking Ordinance of Hong Kong (Cap 155), regulated by the Hong Kong Monetary Authority in Hong Kong and a Registered Institution as defined in the Securities and Futures Ordinance of Hong Kong (Cap.571) regulated by the Securities and Futures Commission in Hong Kong. The Bank, its employees and discretionary accounts managed by its Singapore Office/Hong Kong Office may have long or short positions or may be otherwise interested in any of the investment products (including derivatives thereof) referred to in this document and may from time to time dispose of any such investment products. The Bank forms part of the OCBC Group (being for this purpose Oversea-Chinese Banking Corporation Limited (“OCBC Bank”) and its subsidiaries, related and affiliated companies). OCBC Group, their respective directors and/or employees (collectively “Related Persons”) may have interests in the investment products or the issuers mentioned herein. Such interests include effecting transactions in such investment products, and providing broking, investment banking and other financial services to such issuers. OCBC Group and its Related Persons may also be related to, and receive fees from, providers of such investment products. There may be conflicts of interest between OCBC Bank, the Bank, OCBC Investment Research Private Limited, OCBC Securities Private Limited or other members of the OCBC Group and any of the persons or entities mentioned in this report of which the Bank and its analyst(s) are not aware due to OCBC Bank’s Chinese Wall arrangement.

The Bank adheres to a group policy (as revised and updated from time to time) that provides how entities in the OCBC Group manage or eliminate any actual or potential conflicts of interest which may impact the impartiality of research reports issued by any research analyst in the OCBC Group.

If this material pertains to an offer, it may only be offered (i) in Hong Kong, to qualified Private Banking Customers and Professional Investors (as defined under the Securities and Futures Ordinance); (ii) in Singapore, to Accredited Investors (as defined under the Securities and Futures Act 2001); and (iii) in the Dubai International Financial Center, to Professional Clients (as defined under the Dubai Financial Services Authority rules). No other persons may act on the contents of the material.  

Other Disclosures

 

Singapore

 

Where this material relates to structured deposits, this clause applies:

The product is a structured deposit. Structured deposits are not insured by the Singapore Deposit Insurance Corporation. Unlike traditional deposits, structured deposits have an investment element and returns may vary. You may wish to seek independent advice from a financial adviser before making a commitment to purchase this product. In the event that you choose not to seek independent advice from a financial adviser, you should carefully consider whether this product is suitable for you.

Where this material relates to dual currency investments, this clause applies:

The product is a dual currency investment. A dual currency investment product (“DCI”) is a derivative product or structured product with derivatives embedded in it. A DCI involves a currency option which confers on the deposit-taking institution the right to repay the principal sum at maturity in either the base or alternate currency. Part or all of the interest earned on this investment represents the premium on this option.

By purchasing this DCI, you are giving the issuer of this product the right to repay you at a future date in an alternate currency that is different from the currency in which your initial investment was made, regardless of whether you wish to be repaid in this currency at that time. DCIs are subject to foreign exchange fluctuations which may affect the return of your investment. Exchange controls may also be applicable to the currencies your investment is linked to. You may incur a loss on your principal sum in comparison with the base amount initially invested. You may wish to seek advice from a financial adviser before making a commitment to purchase this product. In the event that you choose not to seek advice from a financial adviser, you should carefully consider whether this product is suitable for you.

Hong Kong

This document has not been delivered for registration to the Registrar of Companies in Hong Kong and its contents have not been reviewed by any regulatory authority in Hong Kong. Accordingly: (i) the shares/notes may not be offered or sold in Hong Kong by means of any document other than to persons who are "Professional Investors" within the meaning of the Securities and Futures Ordinance (Cap. 571) of Hong Kong and the Securities and Futures (Professional Investor) Rules made thereunder or in other circumstances which do not result in the document being a "prospectus" within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance; and (ii) no person may issue any invitation, advertisement or other document relating to the shares/notes whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the shares/notes which are or are intended to be disposed of only to persons outside Hong Kong or only to "Professional Investors" within the meaning of the Securities and Futures Ordinance and the Securities and Futures (Professional Investor) Rules made thereunder.

The product may involve derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it. If you have any doubt, you should seek independent professional financial, tax and/or legal advice as you deem necessary.

Where this material relates to a Complex Product, this clause applies:

Warning Statement and Information about Complex Product

(Applicable to accounts managed by Hong Kong Relationship Manager)

  • Investor should exercise caution in relation to Complex Products;
  • Investor should take note that the past performance of a Complex Product is not indicative of future performance;
  • All Complex Products offered by the Bank are only available to Professional Investors (except for derivative fund without loss absorption features which have been authorized by the Hong Kong Securities and Futures Commission (“SFC”) and listed derivatives); and
  • All Complex Products are not principal protected.

Where this material relates to a Complex Product – funds and ETFs, this clause applies additionally:

  • For Complex Products where offering documents or information provided by the issuer have not been reviewed by the SFC, investors should exercise caution in relation to the offer and take note that such offering documents have not been reviewed by the SFC;
  • For Complex Products described as having been authorised by the SFC, investors should take note that the authorisation does not amount to an official recommendation and that the SFC’s authorisation is not a recommendation or endorsement of that Complex Product nor does it guarantee the commercial merits of that Complex Product or its performance.

Where this material relates to a Complex Product (Options and its variants, Swap and its variants, Accumulator and its variants, Reverse Accumulator and its variants, Forwards), this clause applies additionally: 

  • Investor may incur losses which exceed the amount invested.

Where this material relates to a Loss Absorption Product, this clause applies:

Warning Statement and Information about Loss Absorption Products

(Applicable to accounts managed by Hong Kong Relationship Manager)

Before you invest in any Loss Absorption Product (as defined by the Hong Kong Monetary Authority), please read and ensure that you understand the features of a Loss Absorption Product, which may generally have the following features:

  • The product is subject to the risk of being written down or converted to ordinary shares (as the case may be);
  • The contingent write-down or conversion may happen upon certain circumstances (e.g. at the point of non-viability or the capital ratio falls to a specified level), and the product may potentially result in a substantial loss;
  • The product is a high risk transaction and a Complex Product, as the circumstances in which the product may be required to bear loss are difficult to predict and ex ante assessments of the quantum of loss will also be highly uncertain;
  • The product is targeted at professional investors only and is generally not suitable for retail clients;
  • The credit ranking of the product is usually subordinated. In the event of liquidation or insolvency of the issuer, investors would only be entitled to be paid after other senior creditors are paid and this may result in a substantial loss of the amount invested.

Where this material relates to a certificate of deposit, this clause applies:

It is not a protected deposit and is not protected by the Deposit Protection Scheme in Hong Kong.

Where this material relates to a structured deposit, this clause applies:

It is not a protected deposit and is not protected by the Deposit Protection Scheme in Hong Kong.

Where this material relates to a structured product, this clause applies:

This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it. If you are in any doubt about the risks involved in the product, you may clarify with the intermediary or seek independent professional advice.

 

Dubai International Financial Center

Where this material relates to structured products and bonds, this clause applies:

The Distributor represents and agrees that it has not offered and will not offer the product to any person in the Dubai International Financial Centre unless such offer is an “Exempt Offer” in accordance with the Market Rules of the Dubai Financial Services Authority (the “DFSA”).

The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers.

The DFSA has not approved the Information Memorandum or taken steps to verify the information set out in it, and has no responsibility for it.

The product to which this document relates may be illiquid and/or subject to restrictions in respect of their resale. Prospective purchasers of the products offered should conduct their own due diligence on the products.

Please make sure that you understand the contents of the relevant offering documents (including but not limited to the Information Memorandum or Offering Circular) and the terms set out in this document. If you do not understand the contents of the relevant offering documents and the terms set out in this document, you should consult an authorised financial adviser as you deem necessary, before you decide whether or not to invest.

Where this material relates to a fund, this clause applies:

This Fund is not subject to any form of regulation or approval by the Dubai Financial Services Authority (“DFSA”). The DFSA has no responsibility for reviewing or verifying any Prospectus or other documents in connection with this Fund. Accordingly, the DFSA has not approved the Prospectus or any other associated documents nor taken any steps to verify the information set out in the Prospectus, and has no responsibility for it. The Units to which this Fund relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers should conduct their own due diligence on the Units. If you do not understand the contents of this document you should consult an authorized financial adviser. Please note that this offer is intended for only Professional Clients and is not directed at Retail Clients.

These are also available for inspection, during normal business hours, at the following location:

Bank of Singapore

Office 30-34 Level 28

Central Park Tower

DIFC, Dubai

U.A.E

Cross Border Disclaimer and Disclosures

Refer to https://www.bankofsingapore.com/Disclaimers_and_Disclosures.html for cross-border marketing disclaimers and disclosures.

Author:
Eli Lee
Chief Investment Strategist
Was this page useful?